2022-08-31 08:00 Regulatory Interim
Significant events during the first quarter · Results with DiviTum®TKa at ASCO · DiviTum®TKa highlighted at ASCO in an oral presentation · Biovica’s CFO will terminate employment in December 2022 ·...
2022-06-16 08:00 Regulatory Interim
Significant events during the fourth quarter Significant events after the end of the period Audiocast: When: 16 June 2022 at 15.00 CET Where: https://tv.streamfabriken.com/biovica-international-q4-2021-2022 Phone numbers: SE: +46856642692, DK: +4578723252...
2022-03-15 08:00 Regulatory Interim
Significant events during the third quarter Significant events after the end of the period Audiocast: When: 15 March 2022 at 3 PM CET Where: https://tv.streamfabriken.com/biovica-international-q3-2021-2022 Phone numbers: SE: +46850558356, DK: +4582333194...
2021-12-01 07:30 Regulatory Interim
Significant events during the second quarter Significant events after the end of the period Audiocast: When: 1 December 2021 at 3 PM CET Where: https://tv.streamfabriken.com/biovica-international-q2-2021-2022 Phone numbers: SE: +46850558350, DK: +4578150109...
2021-08-31 08:00 Regulatory Interim
Significant events during the first quarter Significant events after the end of the period Audiocast: When: 2 September 2021 at 10:00 AM CET Where: https://tv.streamfabriken.com/biovica-international-q1-2021-2022 Phone numbers: SE: +46850558365, DK: +4578150108...
2021-06-17 08:00 Regulatory Interim
Preparations for the launch of DiviTum®TKa Significant events during the fourth quarter Significant events after the end of the period Audiocast: When: 18 June 2021 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q4-2020-2021...
2021-03-18 08:00 Regulatory Interim
FDA resumes review of DiviTum®TKa submission Significant events during the third quarter Significant events after the end of the period Audiocast: When: 18 March 2021 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q3-2020-2021...
2020-12-03 08:00 Regulatory Interim
Convincing study results and application submitted to the FDA - commercialization just around the corner Significant events during the second quarter · Clinical validation, which is the last step required for the FDA application, has been completed...
2020-08-27 08:00 Regulatory Interim
Clinical validation completed, work with the FDA submission in the final phase Significant events during the fourth quarter Significant events after the end of the period CEO’s comments During the quarter, we took important steps towards achieving...
2020-06-05 08:00 Regulatory Interim
Preparations for the launch of DiviTum® have started Significant events during the fourth quarter Significant events after the end of the period CEO’s comments Biovica has had yet another eventful quarter. We have focused our efforts on the...

Some of our Collaborations

>3200

Numbers of patients in studies

24

Publications

10

Pharma Contracts